{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:20Z","timestamp":1793242340540,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Dracopoulos and Hankins Uveitis Funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucous membrane pemphigoid with ocular involvement (oMMP) is an autoimmune disease that results in chronic conjunctivitis, conjunctival scarring, and if left untreated, permanent vision loss. oMMP is quite rare with incidence rates between one in 12,000 to one in 60,000, but there is a lack of large population-based studies that focus solely on oMMP. Thus, we sought to examine the cumulative and annual incidence and prevalence of oMMP in the TriNetX database and compared these findings to the US population for greater generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study utilised International Classification of Disease, 10th edition (ICD-10) codes to determine the yearly and cumulative incidence and prevalence, demographics, ocular complications, and immunosuppressant treatments prescribed for oMMP from 2013 to 2023. TriNetX software was used to analyze the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 4052 patients were diagnosed with oMMP with a mean age of 73 years (SD\u2009=\u200914; range 18\u201390). The majority of patients were female (n\u2009=\u20092604 64.26%) and non-Hispanic, white (n\u2009=\u20093098, 76.46%). Prednisone was the most common systemic medication prescribed to 40% of patients. The most used immunosuppressive drug was mycophenolate mofetil (21%). Glaucoma was the most common ocular complication (n\u2009=\u2009375, 9.25%). Between 2013 and 2023, there was a continuous rise in the cumulative incidence and prevalence rates. The 11-year cumulative incidence and prevalence were 1.41per 100,000 persons and 6.72 per 100,000 persons, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to current literature, the TriNetX population with oMMP had similar demographics and immunosuppressant use, but showed a higher incidence and an overall increasing prevalence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04040-5","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:58:29Z","timestamp":1759917509000},"page":"3257-3261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9016-7272","authenticated-orcid":false,"given":"Camellia","family":"Edalat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-8651","authenticated-orcid":false,"given":"Paulina","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Berkenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"4040_CR1","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/biom12101461","volume":"12","author":"L Shi","year":"2022","unstructured":"Shi L, Li X, Qian H. Anti-laminin 332-type mucous membrane pemphigoid. Biomolecules. 2022;12:1461 https:\/\/doi.org\/10.3390\/biom12101461.","journal-title":"Biomolecules"},{"key":"4040_CR2","doi-asserted-by":"publisher","first-page":"14714","DOI":"10.1073\/pnas.93.25.14714","volume":"93","author":"S Tyagi","year":"1996","unstructured":"Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA. 1996;93:14714\u20139. https:\/\/doi.org\/10.1073\/pnas.93.25.14714.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4040_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40123-019-0164-z","volume":"8","author":"P Georgoudis","year":"2019","unstructured":"Georgoudis P, Sabatino F, Szentmary N, Palioura S, Fodor E, Hamada S, et al. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. Ophthalmol Ther. 2019;8:5\u201317. https:\/\/doi.org\/10.1007\/s40123-019-0164-z.","journal-title":"Ophthalmol Ther"},{"key":"4040_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2024.02.028","volume":"131","author":"RE Ruiz-Lozano","year":"2024","unstructured":"Ruiz-Lozano RE, Colorado-Zavala MF, Ramos-D\u00e1vila EM, Quiroga-Garza ME, Azar NS, Mousa HM, et al. Ocular mucous membrane pemphigoid: the effect of risk factors at presentation on treatment outcomes. Ophthalmology. 2024;131:1064\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.028.","journal-title":"Ophthalmology"},{"key":"4040_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamadermatol.2021.4773","volume":"158","author":"N van Beek","year":"2022","unstructured":"van Beek N, Kridin K, B\u00fchler E, Kochan AS, St\u00e4nder S, Ludwig RJ, et al. Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol. 2022;158:84\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4773.","journal-title":"JAMA Dermatol"},{"key":"4040_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/ICU.0000000000000517","volume":"29","author":"K Wang","year":"2018","unstructured":"Wang K, Seitzman G, Gonzales JA. Ocular cicatricial pemphigoid. Current Opin Ophthalmol. 2018;29:543\u2013551. https:\/\/doi.org\/10.1097\/ICU.0000000000000517.","journal-title":"Current Opin Ophthalmol"},{"key":"4040_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/01.all.0000244799.33734.d4","volume":"6","author":"M Hingorani","year":"2006","unstructured":"Hingorani M, Lightman S. Ocular cicatricial pemphigoid. Current Opin Allergy Clin Immunol. 2006;6:373\u20138.","journal-title":"Current Opin Allergy Clin Immunol"},{"key":"4040_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.22336\/rjo.2020.38","volume":"64","author":"C Stan","year":"2020","unstructured":"Stan C, Diaconu E, Hopirca L, Petra N, Rednic A, Stan C. Ocular cicatricial pemphigoid. Rom J Ophthalmol. 2020;64:226\u201330.","journal-title":"Rom J Ophthalmol"},{"key":"4040_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11882-005-0078-9","volume":"5","author":"JH Chang","year":"2005","unstructured":"Chang JH, McCluskey PJ. Ocular cicatricial pemphigoid: manifestations and management. Current Allergy Asthma Rep. 2005;5:333\u20138. https:\/\/doi.org\/10.1007\/s11882-005-0078-9.","journal-title":"Current Allergy Asthma Rep"},{"key":"4040_CR10","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","volume":"115","author":"JE Thorne","year":"2008","unstructured":"Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology. 2008;115:2146\u20132152.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2008.08.002.","journal-title":"Ophthalmology"},{"key":"4040_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jtos.2013.02.003","volume":"11","author":"B Sobolewska","year":"2013","unstructured":"Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. Ocular Surf. 2013;11:259\u201366. https:\/\/doi.org\/10.1016\/j.jtos.2013.02.003.","journal-title":"Ocular Surf"},{"key":"4040_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/OPTH.S40319","volume":"6","author":"J Dacosta","year":"2012","unstructured":"Dacosta J. Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case report. Clin Ophthalmol. 2012;6:2093\u201395. https:\/\/doi.org\/10.2147\/OPTH.S40319.","journal-title":"Clin Ophthalmol"},{"key":"4040_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4.","journal-title":"Lancet"},{"key":"4040_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajo.2020.09.029","volume":"223","author":"AS Shifera","year":"2021","unstructured":"Shifera AS, Hong GH, Khan IR, Okeagu C, Thorne JE. Disease relapse after drug-free remission in ocular mucous membrane pemphigoid. Am J Ophthalmol. 2021;223:21\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2020.09.029.","journal-title":"Am J Ophthalmol"},{"key":"4040_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00417-017-3603-3","volume":"255","author":"C You","year":"2017","unstructured":"You C, Lamba N, Lasave AF, Ma L, Diaz MH, Foster CS. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefe\u2019s Arch Clin Exp Ophthalmol. 2017;255:1221\u20138. https:\/\/doi.org\/10.1007\/s00417-017-3603-3.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4040_CR16","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3390\/jcm11144102","volume":"11","author":"ME Baffa","year":"2022","unstructured":"Baffa ME, Corr\u00e0 A, Maglie R, Mariotti EB, Montefusco F, Pipit\u00f2 C, et al. Rituximab in mucous membrane pemphigoid: a monocentric retrospective study in 10 patients with severe\/refractory disease. J Clin Med. 2022;11:4102 https:\/\/doi.org\/10.3390\/jcm11144102.","journal-title":"J Clin Med"},{"key":"4040_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmunity Rev. 2022;21:103036. https:\/\/doi.org\/10.1016\/j.autrev.2022.103036.","journal-title":"Autoimmunity Rev"},{"key":"4040_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cden.2004.07.004","volume":"49","author":"TP Sollecito","year":"2005","unstructured":"Sollecito TP, Parisi E. Mucous membrane pemphigoid. Dental Clin North Am. 2005;49:91\u2013viii. https:\/\/doi.org\/10.1016\/j.cden.2004.07.004.","journal-title":"Dental Clin North Am"},{"key":"4040_CR19","doi-asserted-by":"publisher","unstructured":"Hens D, Wyers L, Claeys KG. Validation of an artificial intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis polyneuropathy as a key example. J Peripher Nerv Syst. 2022 https:\/\/doi.org\/10.1111\/jns.12523","DOI":"10.1111\/jns.12523"},{"key":"4040_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Br\u00f6cker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434\u2013440. https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06976.x.","journal-title":"J Dtsch Dermatol Ges"},{"key":"4040_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/09273948.2018.1455879","volume":"27","author":"GH Hong","year":"2018","unstructured":"Hong GH, Khan IR, Shifera AS, Okeagu C, Thorne JE. Incidence and clinical characteristics of ocular involvement in mucous membrane pemphigoid. Ocular Immunol Inflamm. 2018;27:821\u20135. https:\/\/doi.org\/10.1080\/09273948.2018.1455879.","journal-title":"Ocular Immunol Inflamm"},{"key":"4040_CR22","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.18240\/ijo.2021.11.17","volume":"14","author":"C Cifuentes-Gonz\u00e1lez","year":"2021","unstructured":"Cifuentes-Gonz\u00e1lez C, Amaris-Mart\u00ednez S, Reyes-Guanes J, Uribe-Reina P, de-la-Torre A. Incidence, prevalence, and demographic characteristics of ocular cicatricial pemphigoid in Colombia: data from the National Health Registry 2009-2019. Int J Ophthalmol. 2021;14:1765\u201370. https:\/\/doi.org\/10.18240\/ijo.2021.11.17.","journal-title":"Int J Ophthalmol"},{"key":"4040_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00160769","volume":"82","author":"CS Foster","year":"1992","unstructured":"Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol Adv Ophthalmol. 1992;82:223\u20139. https:\/\/doi.org\/10.1007\/BF00160769.","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"4040_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/bjo.80.4.292","volume":"80","author":"MJ Elder","year":"1996","unstructured":"Elder MJ, Bernauer W, Leonard J, Dart JK. Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol. 1996;80:292\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4040_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","volume":"117","author":"SS Pujari","year":"2010","unstructured":"Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2009.06.060.","journal-title":"Ophthalmology"},{"key":"4040_CR26","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1080\/09273948.2024.2376746","volume":"32","author":"N Bocanegra-Oyola","year":"2024","unstructured":"Bocanegra-Oyola N, Pardo-Pizza D, Cifuentes-Gonz\u00e1lez C, Oliver-Hern\u00e1ndez MV, Romero-Osorio MJ, Romero-Santos S, et al. Clinical characteristics of ocular mucous membrane pemphigoid: a systematic review and meta-analysis. Ocular Immunol Inflamm. 2024;32:2388\u2013404. https:\/\/doi.org\/10.1080\/09273948.2024.2376746.","journal-title":"Ocular Immunol Inflamm"},{"key":"4040_CR27","doi-asserted-by":"publisher","first-page":"e0269724","DOI":"10.1371\/journal.pone.0269724","volume":"17","author":"N Hangartner","year":"2022","unstructured":"Hangartner N, Di Gangi S, Elbl C, Senn O, Bisatz F, Fehr T. Impact of the COVID-19 pandemic on emergency outpatient consultations and admissions of non-COVID-19 patients (ECCO)-A cross-sectional study. PloS ONE. 2022;17:e0269724 https:\/\/doi.org\/10.1371\/journal.pone.0269724.","journal-title":"PloS ONE"},{"key":"4040_CR28","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ophtha.2021.06.011","volume":"128","author":"T Leng","year":"2021","unstructured":"Leng T, Gallivan MD, Kras A, Lum F, Roe MT, Li C, et al. Ophthalmology and COVID-19: the impact of the pandemic on patient care and outcomes: an IRIS\u00ae registry study. Ophthalmology. 2021;128:1782\u20134. https:\/\/doi.org\/10.1016\/j.ophtha.2021.06.011.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04040-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:15Z","timestamp":1764599955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04040-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4040"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04040-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CE: none, MS: none, JET: ACTG, NEI (grant support); Canfield, Clearview, Gilead, Guidepoint, Merck, UpToDate (consulting); Sanofi (DSMB); Tarsier (Advisory Board, Stock Options); PL: none, MB: Sanofi; Comprehensive Cancer Network.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}